When is enough ... enough? Developing consensus of definition of failure of immune tolerance induction in patients with haemophilia and inhibitors

Haemophilia

Volumn 20, Issue 4, 2014, Pages

  Barnes, C ^a   Brown, S A ^b,c   Curtin, J ^d   Dunkley, S ^e  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

^b ROYAL CHILDREN'S HOSPITAL   (Australia)

^c Department of Haematology Pathology Queensland ^*  (Australia)

^d CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^e ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

Delphi approach; Haemophilia; Immune tolerance induction; Inhibitor; Treatment failure

Indexed keywords

BLOOD CLOTTING FACTOR 8; THROMBOPLASTIN;

ARTICLE; AUSTRALIA; BLEEDING; CLINICAL PRACTICE; HEMOPHILIA; HUMAN; IMMUNE TOLERANCE INDUCTION; IMMUNOLOGICAL TOLERANCE; PHENOTYPE; PRIORITY JOURNAL; QUESTIONNAIRE; TREATMENT FAILURE; TREATMENT OUTCOME; CONSENSUS; DECISION MAKING; DELPHI STUDY; HEMOPHILIA A; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT;

CONSENSUS; DECISION MAKING; DELPHI TECHNIQUE; HEMOPHILIA A; HUMANS; IMMUNOSUPPRESSION; THROMBOPLASTIN; TREATMENT FAILURE;

EID: 84904687202     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12442     Document Type: Article

References (22)

1. Coppola A, Minno MNDD, Santagostino E. Optimizing management of immune tolerance induction in patients with severe haemophilia A and inhibitors: towards evidence based approaches. Br J Haematol 2010; 150: 515-28.
2. Michele DMD. Inhibitors: resolving diagnostic and therapeutic dilemmas. Haemophilia 2002; 8: 280-7.
3. Leissinger CA. Prevention of bleeds in hemophilia patients with inhibitors: emerging data and clinical direction. Am J Hematol 2004; 77: 187-93.
4. Scalone L, Mantovani LG, Mannucci PM, Gringeri A. Quality of life is associated to the orthopaedic status in haemophilic patients with inhibitors. Haemophilia 2006; 12: 154-62.
5. Michele DMD, Hoots K, Pipe SW, Rivard GE, Santagostino E. International workshop on immune tolerance induction; consensus recommendations. Haemophilia 2007; 13: 1-22.
6. Coppola A, Margaglione M, Santagostino E et al. Factor VIII gene (F8) mutations as predictors of outcome in immune tolerance induction of hemophilia A patients with high-responding inhibitors. J Thromb Haemost 2009; 7: 1809-15.
7. Dimichele D. The North American Immune Tolerance Registry: contributions to the thirty year experience with immune tolerance therapy. Haemophilia 2009; 15: 320-8.
8. DiMichele DM, Kroner BL. The North American Immune Tolerance Registry: practices, outcomes, outcome predictors. Thromb Haemost 2002; 87: 52-7.
9. Haya S, Lopez MF, Aznar JA, Batlle J. Immune tolerance treatment in haemophilia patients with inhibitors: the Spanish Registry. Haemophilia 2001; 7: 154-9.
10. Lenk H. The German National Immune Tolerance Registry, 1997 update. Study Group of German Haemophilia Centres. Vox Sang 1999; 77(Suppl. 1): 28-30.
11. Mariani G, Kroner B. Immune tolerance in hemophilia with factor VIII inhibitors: predictors of success. Haematologica 2001; 86: 1186-93.
12. McMurray A. Three decision-making aids: brain-storming, nominal group, and Delphi technique. J Nurs Staff Dev 1994; 10: 62-5.
13. Hsu CC, Sandford BA. The Delphi Technique: making sense of consensus. Practical Assess Res Eval 2007; 12: 1-8.
14. Hassan F, Keeney S, McKenna H. Research guidelines for the Delphi survey technique. J Adv Nurs 2000; 32: 1008-15.
15. Keeney S, Hassan F, McKenna H. A critical review of the Delphi technique as a research methodology for nursing. Int J Nurs Stud 2001; 38: 195-200.
16. Graham B, Regehr G, Wright JG. Delphi as a method to establish consensus for diagnostic criteria. J Clin Epidemiol 2003; 56: 1150-6.
17. Mariani G, Siragusa S, Kroner BL. Immune tolerance induction in hemophilia A: a review. Semin Thromb Hemost 2003; 29: 69-76.
18. DiMichele D, Hoots WK, Pipe SW, Rivard GE, Santagostino E. International workshop on immune tolerance induction: consensus recommendations. Haemophilia 2007; 13: 1-22.
19. Hay CR, Brown S, Collins PW, Keeling DM, Liesner R. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation. Br J Haematol 2006; 133: 591-605.
20. Hay CR, DiMichele D. The principal results of the International Immune Tolerance study: a randomized dose comparison. Blood 2012; 119: 1335-44.
21. Gringeri A, Mantovani LG, Scalone L, Mannucci PM. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS study group. Blood 2003; 102: 2358-63.
22. Young G, Auerswald G, Jimenez-Yuste V et al. When should prophylaxis therapy in inhibitor patients be considered? Haemophilia 2011; 1: e849-57.